نتایج جستجو برای: high dose cytarabine

تعداد نتایج: 2292508  

2016
Steve Hu Pranshu Bansal David Lynch Cristhiam Mauricio Rojas Hernandez Zoneddy Dayao

BACKGROUND Hemophagocytic lymphohistiocytosis is becoming an increasingly recognized disorder in adults. Classical Hodgkin lymphoma is a relatively uncommon etiology of hemophagocytic lymphohistiocytosis and may complicate treatment options. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin are discussed here as a treatment regimen. CASE PRESENTATION A 66-year-old ...

Journal: :Cancer research 1998
C D Bloomfield D Lawrence J C Byrd A Carroll M J Pettenati R Tantravahi S R Patil F R Davey D T Berg C A Schiffer D C Arthur R J Mayer

Advances in the treatment of acute myeloid leukemia (AML) have occurred with the introduction of new therapies including high-dose cytarabine and the identification of powerful prognostic factors such as cytogenetics that predict for long-term outcome. To date, the prognostic impact of cytarabine dose escalation within various cytogenetic groups of AML has not been assessed. We describe 285 new...

2010
K. Brandt K. Schäkel F. Stölzel J. Janschek G. Ehninger M. Schaich

Cytarabine is an effective drug in the treatment of haematological malignancies. The therapy is associated with various complications. Frequencies of dermatological side-effects range from 2-72% and occur most commonly after high-dose regimens. Although most cutaneous reactions are mild and resolve spontaneously within several days, they may result in an increased risk of infection and alterati...

Journal: :Blood 2013
Eric R Gamazon Jatinder K Lamba Stanley Pounds Amy L Stark Heather E Wheeler Xueyuan Cao Hae K Im Amit K Mitra Jeffrey E Rubnitz Raul C Ribeiro Susana Raimondi Dario Campana Kristine R Crews Shan S Wong Marleen Welsh Imge Hulur Lidija Gorsic Christine M Hartford Wei Zhang Nancy J Cox M Eileen Dolan

A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colo...

Journal: :Blood 1993
K S Zuckerman D C Case R A Gams E F Prasthofer

An intensive chemotherapy regimen (EVDAC), including high-dose epirubicin, vincristine, and dexamethasone followed by cyclophosphamide and high-dose cytarabine, was administered to 54 untreated adults with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 59, 61% were Ann Arbor Stage IV, 57% had "B" symptoms, 50% had serum lactate dehydrogenase greater than 250 U/L, a...

Journal: :Blood 1992
G Schiller J Gajewski M Territo S Nimer M Lee T Belin R Champlin

Modern induction chemotherapy produces 60% to 80% complete remissions in adults with newly diagnosed acute myelogenous leukemia. A major challenge is to eradicate subclinical disease in remission and prevent leukemic relapse. We analyzed the long-term results of high-dose cytarabine-anthracycline consolidation chemotherapy without maintenance treatment and examined the effect of major prognosti...

2008
Stefan Faderl Farhad Ravandi Xuelin Huang Guillermo Garcia-Manero Alessandra Ferrajoli Zeev Estrov Gautam Borthakur Srdan Verstovsek Deborah A. Thomas Monica Kwari Hagop M. Kantarjian

We previously reported the feasibility of clofarabine and cytarabine combinations in AML. Questions remain as to (1) the therapeutic advantage of this combination and (2) the role of lower doses of clofarabine and cytarabine in older patients. We have conducted an adaptively randomized study of lower-dose clofarabine with or without low-dose cytarabine in previously untreated patients with AML ...

Journal: :Onkologie 2007
Beate Gleissner Richard Schlenk Martin Bornhäuser Wolfgang E Berdel

The value of the combination of gemtuzumab ozogamicin (GO) and chemotherapy for the treatment of acute myeloid leukemia (AML) is currently analyzed within clinical trials. GO (6 mg/m2) and standard-dose cytarabine (100 mg/m2) is evaluated for the treatment of newly diagnosed AML in elderly patients in the SAL phase II trial. Preliminary results of the MRC AML15 trial support the application of ...

Journal: :Haematologica 2007
Arnaud Pigneux Virginie Perreau Eric Jourdan Norbert Vey Nicole Dastugue Françoise Huguet Jean-Jacques Sotto L Rachid Salmi Norbert Ifrah Josy Reiffers

BACKGROUND AND OBJECTIVES Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation. DESIGN AND METHODS A multicenter randomized t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید